The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Spain in focus after bailout rumours

Fri, 08th Jun 2012 16:37

- Spanish bailout could be on the cards- Fitch downgrades Spain to BBB- Investors look ahead of Chinese data this weekendRumours about an imminent recapitalisation of Spain's banking sector and concerns over global growth were doing the rounds on Friday, yet the Footsie still managed to pare losses by the close.According to a Financial Times article this afternoon, Spain may ask for bailout aid for its financial sector as early as tomorrow during a conference call with European finance ministers.Fitch Ratings said last night that the "likely 'fiscal cost'" of restructuring and recapitalising the Spanish banking sector would be between €60bn and €100bn in a worst-case scenario. This came as the ratings agency downgraded its sovereign debt rating for the country from A to BBB. Also weighing on sentiment today were yesterday's comments from Federal Reserve Chairman Ben Bernanke who "performed his usual trick of depressing the markets", according to Craig Erlam from Alpari. Analysts were hoping for hints of imminent stimulus measures but Bernanke failed to say whether the Fed would be embarking on QE3 any time soon. "The positive sentiment from earlier in the week has been knocked over the last 24 hours. With the ECB, BOE and Fed all deciding against further QE or rate cuts this week, it's surprising that the markets have held up as well as they have," Erlam said in an emailed note.This afternoon, President Barack Obama said that the ongoing crisis in Europe could have a "potential impact" on the US economy as he urged Eurozone leaders to act: "The sooner they act the more decisive and concrete their action, the sooner people and markets will regain some confidence."Investors will still be digesting the recent interest rate cut from China, which initially spurred impressive gains for equity markets on Thursday. However, ahead of some key inflation and industrial production figures due out this weekend from the world's second-largest economy, some analysts are questioning whether the rate cut was a pre-emptive move ahead of what could be some disappointing data. FTSE 100: Miners down, defensives upVedanta, Kazakhmys, Antofagasta, Xstrata, Rio Tinto, Glencore and ENRC were among the worst performers of the day as investors fled from risk. BHP Billiton was also among the fallers after Bank of America Merrill-Lynch reduced its profit forecasts for the group on the back of lower oil prices estimates. Kazakhmys announced late on that it has signed an agreement with JSC RusHydro, one of Russia's largest power generating companies, to consider establishing a hydro-electric power joint venture. The defensive utilities sector benefited from its 'safe-haven' appeal today with Severn Trent, Centrica, United Utilities, SSE and National Grid making gains. Credit Suisse raised its target price for National Grid today after saying that Ofgem's new RIIO regulation presents a £2.5bn opportunity for the group.Capita was a strong performer after JP Morgan Cazenove reiterated its overweight rating on the outsourcing giant.Pharmaceuticals leviathan GlaxoSmithkline was also in demand after extending the offer period for its hostile take-over of US sector peer Human Genome Sciences (HGS) by a further three weeks.FTSE 250: Bumi leaps on mining contractMining firm Bumi leapt into the top spot on the second-tier index after reportedly signing a contract to sell 50m metric tons of coal. According to Dow Jones Newswires, the coal will be sold at an average price of $80 per ton this calendar year. The firm's Resource Director, Dileep Srivastava, was quoted as saying: "The sales contract is 67% of our 75-million-ton output guidance for 2012." Heading the other way was energy markets-focused engineer Lamprell which was battered after sneaking out a profit warning on Thursday after the London market closed, saying that it now expects to make a half-year loss of between $15m and $20m, compared with earlier guidance of "a small loss". The group also said that Chairman Jonathan Silver would step down. "We continue to believe that management's credibility has fundamentally deteriorated," Nomura said in a research note this morning.FTSE 100 - RisersCapita (CPI) 649.50p +2.85%Severn Trent (SVT) 1,782.00p +2.71%Centrica (CNA) 315.20p +2.20%British Sky Broadcasting Group (BSY) 696.00p +2.20%Standard Life (SL.) 220.40p +1.90%United Utilities Group (UU.) 680.50p +1.80%Vodafone Group (VOD) 171.50p +1.51%Shire Plc (SHP) 1,879.00p +1.51%Kingfisher (KGF) 279.00p +1.31%Reed Elsevier (REL) 493.40p +1.31%FTSE 100 - FallersVedanta Resources (VED) 935.50p -5.07%Rio Tinto (RIO) 2,869.00p -4.84%Eurasian Natural Resources Corp. (ENRC) 423.80p -3.94%Evraz (EVR) 279.20p -3.19%Kazakhmys (KAZ) 705.00p -3.16%BHP Billiton (BLT) 1,767.00p -2.91%Anglo American (AAL) 2,074.00p -2.77%Petrofac Ltd. (PFC) 1,535.00p -2.66%Schroders (Non-Voting) (SDRC) 976.00p -2.59%Antofagasta (ANTO) 1,060.00p -2.21%FTSE 250 - RisersBumi (BUMI) 365.00p +11.93%Atkins (WS) (ATK) 694.50p +6.27%New World Resources A Shares (NWR) 326.10p +4.19%Bellway (BWY) 770.50p +3.56%Ophir Energy (OPHR) 615.00p +3.36%Grainger (GRI) 90.00p +2.97%Synergy Health (SYR) 887.00p +2.60%RPS Group (RPS) 202.00p +2.54%Bovis Homes Group (BVS) 432.30p +2.32%Brown (N.) Group (BWNG) 233.60p +1.96%FTSE 250 - FallersLamprell (LAM) 84.50p -22.26%Kesa Electricals (KESA) 49.81p -7.93%Afren (AFR) 108.40p -7.51%Lonmin (LMI) 747.50p -5.62%Essar Energy (ESSR) 117.40p -5.55%Anglo Pacific Group (APF) 238.80p -5.50%Ocado Group (OCDO) 94.90p -5.10%Imagination Technologies Group (IMG) 487.80p -4.17%Avocet Mining (AVM) 157.00p -3.98%Hays (HAS) 72.25p -3.73%BC
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.